Clinical Trials Logo

Relapsed Leukemia clinical trials

View clinical trials related to Relapsed Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05519384 Recruiting - Refractory Leukemia Clinical Trials

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Start date: September 14, 2022
Phase: Early Phase 1
Study type: Interventional

This study is a prospective, single-center, single-arm exploratory clinical study, aiming to complete the preliminary clinical observation of 12 children with relapsed/refractory acute myeloid leukemia treated with JK500 cell injection to evaluate the safety of clinical infusion and the initial efficacy of JK500 cell injection in the treatment of children with relapsed/refractory acute myeloid leukemia.

NCT ID: NCT05495035 Recruiting - Refractory Leukemia Clinical Trials

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in treating R/R Ph+ALL children, and to preliminarily establish the recommended dose of olverembatinib and APG-2575 for children based on the above results.